• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

印度南部一家三级医疗中心非小细胞肺癌的临床病理及免疫组化特征

Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India.

作者信息

Shankar Shanmugapriya, Thanasekaran Vijayalakshmi, Dhanasekar T, Duvooru Prathiba

机构信息

Department of Pathology, Sri Ramachandra University, Chennai, Tamil Nadu, India.

Department of Pulmonology, Sri Ramachandra University, Chennai, Tamil Nadu, India.

出版信息

Lung India. 2014 Jan;31(1):23-8. doi: 10.4103/0970-2113.125889.

DOI:10.4103/0970-2113.125889
PMID:24669077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3960804/
Abstract

BACKGROUND

Lung cancer is a highly aggressive malignancy causing high morbidity and mortality. An increasing incidence of lung cancer has been observed in India. Currently, the classification of lung carcinoma has gone beyond small cell lung carcinoma and non-small cell lung carcinoma (NSCLC). Precise subtyping of poorly differentiated NSCLC into adenocarcinoma and squamous cell carcinoma has a direct impact on patient management and prognosis. With this background, many molecules are under study for developing targeted therapies. Epidermal growth factor receptor (EGFR) is one such biomarker considered to be useful in targeted therapy for adenocarcinoma.

OBJECTIVE

The aim of this study was to subtype poorly differentiated NSCLC based on the expression of thyroid transcription factor-1 (TTF-1) and p-63 and to evaluate EGFR expression in adenocarcinomas.

MATERIALS AND METHODS

A retrospective analysis of 84 cases of poorly differentiated carcinomas of the lung was performed. Paraffin sections were immunostained with TTF-1 and p-63 and the tumors were subtyped. EGFR expression was assessed in adenocarcinomas by immunohistochemistry.

RESULTS

Fifty-five percent of the NSCLC were adenocarcinoma, with a peak incidence between 61 and 70 years of age and a male predominance. EGFR was expressed in 89% of the adenocarcinomas.

CONCLUSIONS

Poorly differentiated non-small cell carcinoma can be subtyped by immunohistochemical markers and hence has a direct impact on the current therapeutic strategies.

摘要

背景

肺癌是一种具有高度侵袭性的恶性肿瘤，导致高发病率和高死亡率。在印度，肺癌的发病率呈上升趋势。目前，肺癌的分类已超越小细胞肺癌和非小细胞肺癌（NSCLC）。将低分化NSCLC精确亚型化为腺癌和鳞状细胞癌对患者的治疗管理和预后有直接影响。在此背景下，许多分子正在研究用于开发靶向治疗。表皮生长因子受体（EGFR）就是这样一种被认为在腺癌靶向治疗中有用的生物标志物。

目的

本研究的目的是基于甲状腺转录因子-1（TTF-1）和p-63的表达对低分化NSCLC进行亚型分类，并评估腺癌中EGFR的表达。

材料与方法

对84例低分化肺癌病例进行回顾性分析。石蜡切片用TTF-1和p-63进行免疫染色，并对肿瘤进行亚型分类。通过免疫组织化学评估腺癌中EGFR的表达。

结果

55%的NSCLC为腺癌，发病高峰年龄在61至70岁之间，男性居多。89%的腺癌表达EGFR。

结论

低分化非小细胞癌可通过免疫组织化学标志物进行亚型分类，因此对当前的治疗策略有直接影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/a053d415b033/LI-31-23-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/071692eeabd0/LI-31-23-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/75f106604017/LI-31-23-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/ff74cb8d6021/LI-31-23-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/befeccfef7a4/LI-31-23-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/52d9a03d8759/LI-31-23-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/173784772fcc/LI-31-23-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/b21f51fc6a04/LI-31-23-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/db622683f7a8/LI-31-23-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/eed7394eac59/LI-31-23-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/8d41d7121315/LI-31-23-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/a053d415b033/LI-31-23-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/071692eeabd0/LI-31-23-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/75f106604017/LI-31-23-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/ff74cb8d6021/LI-31-23-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/befeccfef7a4/LI-31-23-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/52d9a03d8759/LI-31-23-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/173784772fcc/LI-31-23-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/b21f51fc6a04/LI-31-23-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/db622683f7a8/LI-31-23-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/eed7394eac59/LI-31-23-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/8d41d7121315/LI-31-23-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde8/3960804/a053d415b033/LI-31-23-g014.jpg

相似文献

1
Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India.印度南部一家三级医疗中心非小细胞肺癌的临床病理及免疫组化特征
Lung India. 2014 Jan;31(1):23-8. doi: 10.4103/0970-2113.125889.
2
Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.非小细胞肺癌的游离 DNA 分子谱分析及应用：在一家三级医院的研究。
J Cancer Res Ther. 2021 Oct-Dec;17(6):1389-1396. doi: 10.4103/jcrt.JCRT_99_20.
3
Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.在缺乏形态学分化的非小细胞肺癌活检标本的分类：包含 TTF-1、napsin A、p63 和 CK5/6 的免疫组织化学组合的应用。
Am J Surg Pathol. 2011 Jan;35(1):15-25. doi: 10.1097/PAS.0b013e3182036d05.
4
[Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].[低分化实性肺癌的组织学亚型与表皮生长因子受体突变及ALK基因重排的分子检测：167例分析]
Zhonghua Bing Li Xue Za Zhi. 2018 Jun 8;47(6):432-437. doi: 10.3760/cma.j.issn.0529-5807.2018.06.009.
5
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].非小细胞肺癌中PD-1与PD-L1表达及表皮生长因子受体突变的相关性研究
Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):623-631. doi: 10.3779/j.issn.1009-3419.2021.102.31. Epub 2021 Aug 30.
6
The role of the cytopathologist in subtyping and epidermal growth factor receptor testing in non-small cell lung cancer: An institutional experience.细胞病理学家在非小细胞肺癌亚型分类及表皮生长因子受体检测中的作用：一项机构经验。
Cytopathology. 2017 Oct;28(5):371-377. doi: 10.1111/cyt.12445. Epub 2017 Jul 21.
7
Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype.非小细胞肺癌病理亚型的细胞组织学一致性：回顾性分析 602 例细针抽吸活检与 9 年随访手术标本，并分析未能确定亚型的相关因素
Lung Cancer. 2012 Sep;77(3):501-6. doi: 10.1016/j.lungcan.2012.05.091. Epub 2012 May 31.
8
Immunohistochemical staining for thyroid transcription factor-1: a helpful aid in discerning primary site of tumor origin in patients with brain metastases.甲状腺转录因子-1免疫组化染色：有助于鉴别脑转移瘤患者肿瘤的原发部位。
Hum Pathol. 2002 Jun;33(6):642-5. doi: 10.1053/hupa.2002.124910.
9
Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas.非小细胞肺癌的免疫组织化学标志物的最佳组合：低分化区组织微阵列研究。
Lung Cancer. 2012 Apr;76(1):51-5. doi: 10.1016/j.lungcan.2011.09.008. Epub 2011 Oct 5.
10
[Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer].非小细胞肺癌患者表皮生长因子受体基因突变、临床病理特征与预后的关系
Zhonghua Bing Li Xue Za Zhi. 2011 Oct;40(10):679-82.

引用本文的文献

1
Evaluation of TTF-1, Napsin A, p40, and p63 in the Subtyping of Non-Small Cell Lung Carcinoma: A Cross-Sectional Study from India.TTF-1、Napsin A、p40和p63在非小细胞肺癌亚型分类中的评估：一项来自印度的横断面研究。
Iran J Pathol. 2025 Summer;20(3):297-306. doi: 10.30699/ijp.2025.2044252.3371. Epub 2025 Jul 1.
2
Programmed Death Ligand -1 and Gene Mutation Characterization of Lung Malignancies in Patients at a Rural Hospital in Central India.程序性死亡配体-1 与印度中部农村医院肺癌患者基因突变特征。
Asian Pac J Cancer Prev. 2023 Jun 1;24(6):1855-1861. doi: 10.31557/APJCP.2023.24.6.1855.
3
Molecular characterization of lung carcinomas: A study on diagnostic, predictive, and prognostic markers using immunohistochemical analysis at a Tertiary Care Center in Uttarakhand, India.

本文引用的文献

1
Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung.保留组织的抗体鸡尾酒可区分原发性鳞状细胞癌、腺癌和小细胞肺癌。
Arch Pathol Lab Med. 2013 Sep;137(9):1274-81. doi: 10.5858/arpa.2012-0635-OA. Epub 2013 Jan 4.
2
Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test.非小细胞肺癌中表皮生长因子受体免疫组化评分的可重复性：轮次测试。
Arch Pathol Lab Med. 2013 Sep;137(9):1255-61. doi: 10.5858/arpa.2012-0605-OA. Epub 2012 Dec 27.
3
Lung cancer genotype-based therapy and predictive biomarkers: present and future.
肺癌的分子特征：在印度北阿坎德邦的一家三级医疗中心使用免疫组织化学分析对诊断、预测和预后标志物的研究。
J Carcinog. 2021 Oct 7;20:17. doi: 10.4103/jcar.jcar_14_21. eCollection 2021.
4
Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.非小细胞肺癌的生物标志物：印度分子检测共识指南。
Adv Ther. 2019 Apr;36(4):766-785. doi: 10.1007/s12325-019-00903-y. Epub 2019 Mar 12.
5
Adenocarcinoma of the lung with positive epidermal growth factor receptor mutation in pregnancy.孕期发生的伴有表皮生长因子受体突变阳性的肺腺癌
Lung India. 2017 Nov-Dec;34(6):548-551. doi: 10.4103/0970-2113.217574.
6
An Immunohistochemical Study of Anaplastic Lymphoma Kinase and Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Carcinoma.非小细胞肺癌中间变性淋巴瘤激酶和表皮生长因子受体突变的免疫组织化学研究
J Clin Diagn Res. 2017 Jul;11(7):EC22-EC25. doi: 10.7860/JCDR/2017/27941.10279. Epub 2017 Jul 1.
7
Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables.北印度人群肺腺癌中表皮生长因子受体突变：患病率及其与不同临床变量的关系
Indian J Med Paediatr Oncol. 2016 Jul-Sep;37(3):189-95. doi: 10.4103/0971-5851.190356.
基于肺癌基因型的治疗和预测生物标志物：现状与未来。
Arch Pathol Lab Med. 2012 Dec;136(12):1482-91. doi: 10.5858/arpa.2012-0508-RA.
4
Advances in treatment of lung cancer with targeted therapy.肺癌靶向治疗进展。
Arch Pathol Lab Med. 2012 May;136(5):504-9. doi: 10.5858/arpa.2011-0618-RA.
5
Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.非小细胞肺癌中的表皮生长因子受体和K-Ras——相关分子途径及靶向治疗
World J Clin Oncol. 2011 Nov 10;2(11):367-76. doi: 10.5306/wjco.v2.i11.367.
6
Role of genotyping in non-small cell lung cancer treatment: current status.基因分型在非小细胞肺癌治疗中的作用：现状。
Drugs. 2011 Dec 3;71(17):2231-46. doi: 10.2165/11597700-000000000-00000.
7
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).表皮生长因子受体（EGFR）突变在一系列非小细胞肺癌（NSCLC）患者中的存在情况，以及对 EGFR 特异性酪氨酸激酶抑制剂（TKIs）的反应率。
Clin Transl Oncol. 2011 Nov;13(11):812-8. doi: 10.1007/s12094-011-0739-1.
8
Pathology of lung cancer.肺癌病理学。
Clin Chest Med. 2011 Dec;32(4):669-92. doi: 10.1016/j.ccm.2011.08.005.
9
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.EGFR 分子特征在 NSCLC 治疗决策中的作用。
J Clin Pathol. 2012 Jan;65(1):1-7. doi: 10.1136/jclinpath-2011-200275. Epub 2011 Oct 29.
10
Genomic pathology: challenges for implementation.基因组病理学：实施面临的挑战
Arch Pathol Lab Med. 2011 Aug;135(8):967-8. doi: 10.5858/2011-0199-EDI.